SG121778A1 - Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway - Google Patents

Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Info

Publication number
SG121778A1
SG121778A1 SG200303599A SG200303599A SG121778A1 SG 121778 A1 SG121778 A1 SG 121778A1 SG 200303599 A SG200303599 A SG 200303599A SG 200303599 A SG200303599 A SG 200303599A SG 121778 A1 SG121778 A1 SG 121778A1
Authority
SG
Singapore
Prior art keywords
respiratory distress
viral
blockade
reversal
induced systemic
Prior art date
Application number
SG200303599A
Other languages
English (en)
Inventor
Jeff Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Univ Emory
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Biogen Idec Inc filed Critical Univ Emory
Publication of SG121778A1 publication Critical patent/SG121778A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200303599A 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway SG121778A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
SG121778A1 true SG121778A1 (en) 2006-05-26

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200303599A SG121778A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Country Status (27)

Country Link
US (3) US20020001585A1 (fr)
EP (1) EP1119370B1 (fr)
JP (2) JP4713738B2 (fr)
KR (1) KR100888832B1 (fr)
CN (1) CN1200733C (fr)
AT (1) ATE329618T1 (fr)
AU (1) AU777492C (fr)
BR (1) BR9915025A (fr)
CA (1) CA2344049C (fr)
CY (1) CY1105059T1 (fr)
CZ (1) CZ20011272A3 (fr)
DE (1) DE69931944T2 (fr)
DK (1) DK1119370T3 (fr)
EA (1) EA006703B1 (fr)
EE (1) EE04661B1 (fr)
ES (1) ES2267294T3 (fr)
HU (1) HUP0103773A3 (fr)
IL (2) IL142284A0 (fr)
IS (1) IS2514B (fr)
NO (1) NO326905B1 (fr)
NZ (1) NZ510560A (fr)
PL (1) PL195264B1 (fr)
PT (1) PT1119370E (fr)
SG (1) SG121778A1 (fr)
SK (1) SK4662001A3 (fr)
TR (1) TR200100974T2 (fr)
WO (1) WO2000021558A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CN1200733C (zh) * 1998-10-09 2005-05-11 拜奥根有限公司 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (fr) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand pour mediateur d'entree du virus herpes simplex et procedes de mise en oeuvre
DK1674575T3 (da) * 2000-04-12 2010-11-29 Jolla Inst Allergy Immunolog Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse
WO2005000898A2 (fr) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Purification et synthese preferentielle de molecules de liaison
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (fr) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Molecules de liaison multispecifiques comprenant des peptides de connexion
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
WO2009039310A2 (fr) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Inhibiteurs de la voie light utilisés dans le traitement de l'asthme, de l'inflammation des poumons et des voies respiratoires, de la fibrose pulmonaire interstitielle
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003687A1 (fr) * 1995-07-21 1997-02-06 Biogen, Inc. RECEPTEURS SOLUBLES DE LA LYMPHOTOXINE-β, RECEPTEUR ANTI-LYMPHOTOXINE ET ANTICORPS LIGANDS SERVANT D'AGENTS POUR LE TRAITEMENT DE TROUBLES IMMUNOLOGIQUES
US5661004A (en) * 1990-06-27 1997-08-26 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1998017313A2 (fr) * 1996-10-25 1998-04-30 Biogen, Inc. Recepteurs solubles de lymphotoxine beta, anticorps du recepteur d'anti-lymphotoxine et, anticorps du ligand d'anti-lymphotoxine utilises comme agents therapeutiques pour le traitement de maladies immunologiques

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP0672143B1 (fr) 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxine-beta, complexes de lymphotoxines-beta, preparations pharmaceutiques et leurs utilisations therapeutiques
CA2211443A1 (fr) 1995-01-26 1996-08-01 Biogen, Inc. Complexes de lymphotoxine-.alpha./.beta. et anticorps de recepteur anti-lymphotoxine-beta utiles en tant qu'agents anti-tumoraux
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CN1200733C (zh) * 1998-10-09 2005-05-11 拜奥根有限公司 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
TW200416044A (en) * 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661004A (en) * 1990-06-27 1997-08-26 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1997003687A1 (fr) * 1995-07-21 1997-02-06 Biogen, Inc. RECEPTEURS SOLUBLES DE LA LYMPHOTOXINE-β, RECEPTEUR ANTI-LYMPHOTOXINE ET ANTICORPS LIGANDS SERVANT D'AGENTS POUR LE TRAITEMENT DE TROUBLES IMMUNOLOGIQUES
WO1998017313A2 (fr) * 1996-10-25 1998-04-30 Biogen, Inc. Recepteurs solubles de lymphotoxine beta, anticorps du recepteur d'anti-lymphotoxine et, anticorps du ligand d'anti-lymphotoxine utilises comme agents therapeutiques pour le traitement de maladies immunologiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"POTENTIAL BENEFITS AND RISKS OF A THERAPEUTIC INHIBITION OF THE LYMPHOTOXIN-B RECEPTOR PA" *
"ROLE OF LYMPHOTOXIN IN EXPERIMENTAL MODELS OF INFECTIOUS DISEASES" *

Also Published As

Publication number Publication date
IL142284A (en) 2009-11-18
CN1323223A (zh) 2001-11-21
IL142284A0 (en) 2002-03-10
PT1119370E (pt) 2006-09-29
EP1119370A1 (fr) 2001-08-01
US7452530B2 (en) 2008-11-18
IS2514B (is) 2009-06-15
HUP0103773A2 (hu) 2002-01-28
NO326905B1 (no) 2009-03-16
CZ20011272A3 (cs) 2001-09-12
CN1200733C (zh) 2005-05-11
PL347177A1 (en) 2002-03-25
SK4662001A3 (en) 2001-11-06
CY1105059T1 (el) 2010-03-03
WO2000021558A1 (fr) 2000-04-20
DE69931944D1 (de) 2006-07-27
CA2344049C (fr) 2009-12-15
DE69931944T2 (de) 2007-02-08
NZ510560A (en) 2003-09-26
JP2010155852A (ja) 2010-07-15
WO2000021558A9 (fr) 2001-05-25
ATE329618T1 (de) 2006-07-15
US20020001585A1 (en) 2002-01-03
US20090087403A1 (en) 2009-04-02
EE04661B1 (et) 2006-08-15
CA2344049A1 (fr) 2000-04-20
HUP0103773A3 (en) 2003-10-28
KR20010080073A (ko) 2001-08-22
JP2002527403A (ja) 2002-08-27
JP4713738B2 (ja) 2011-06-29
EP1119370B1 (fr) 2006-06-14
EA200100430A1 (ru) 2001-10-22
EA006703B1 (ru) 2006-02-24
BR9915025A (pt) 2001-08-14
US20040198635A1 (en) 2004-10-07
IS5882A (is) 2001-03-09
PL195264B1 (pl) 2007-08-31
ES2267294T3 (es) 2007-03-01
AU777492B2 (en) 2004-10-21
AU6296499A (en) 2000-05-01
DK1119370T3 (da) 2006-10-02
NO20011757D0 (no) 2001-04-06
KR100888832B1 (ko) 2009-03-17
NO20011757L (no) 2001-06-08
EE200100211A (et) 2002-08-15
TR200100974T2 (tr) 2001-11-21
AU777492C (en) 2005-05-26

Similar Documents

Publication Publication Date Title
PL347177A1 (en) Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
MX9805539A (es) Uso de un agonista del receptor activado proliferador de peroxisomas alfa y del receptor activado proliferador de peroxisomas gamma, para el tratamiento del sindrome x.
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
SI1010688T1 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
CA2179183A1 (fr) Antagoniste d'un recepteur de l'interleukine-1 attenuant la gravite de la pancreatite aigue
IL138665A0 (en) Peptide factor
UA41355C2 (uk) Засіб для лікування нейро-сніду
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
WO2002089805A3 (fr) Utilisation d'une therapie de methotrexate intraveineuse, reguliere et a haute dose
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
MY121864A (en) Condensed thienopyrimidines with phosphodiesterase-v inhibiting action.
AP2002002446A0 (en) Method for administering a phosphodiesterase 4 inhibitor.
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
Fujita Experimental studies of stimulated brillouin scattering from KrF laser-produced plasma
IT1299578B1 (it) Uso dell'ubichinone per la produzione di un farmaco efficace nella prevenzione e nel trattamento della degenerazione maculare correlata
GB9220693D0 (en) Protection against fludarabine neurotoxicity in mammeals by inhibitors of equilibrative nucleoside transport